Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2023-07-27
2030-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733
CD19 Chimeric Receptor Expressing T Lymphocytes in B-Cell Non Hodgkin's Lymphoma, ALL & CLL
NCT00586391
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT01045928
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT01419795
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with T-Cell Lymphoma
Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma
Optional Blood Sample and Nail Sample
Participants may provide optional research blood and nail samples for biobanking and future use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optional Blood Sample and Nail Sample
Participants may provide optional research blood and nail samples for biobanking and future use
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
* T-cell prolymphocytic leukemia
* T-cell large granular lymphocytic leukemia
* Chronic lymphoproliferative disorder of NK cells
* Aggressive NK-cell leukemia
* Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
* Chronic active EBV infection of T- and NK-cell type, systemic form
* Hydroa vacciniforme-like lymphoproliferative disorder
* Adult T-cell leukemia/lymphoma
* Extranodal NK/T-cell lymphoma, nasal type
* Enteropathy-associated T-cell lymphoma
* Monomorphic epitheliotropic intestinal T-cell lymphoma
* Intestinal T-cell lymphoma, not otherwise specified (NOS)
* Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
* Hepatosplenic T-cell lymphoma
* Subcutaneous panniculitis-like T-cell lymphoma
* Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
* Sézary syndrome
* Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
* Primary cutaneous Gamma-Delta T-cell lymphoma
* Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
* Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
* Peripheral T-cell lymphoma, not otherwise specified
* Angioimmunoblastic T-cell lymphoma
* Follicular T-cell lymphoma
* Nodal peripheral T-cell lymphoma with TFH phenotype
* Anaplastic large cell lymphoma, ALK-positive
* Anaplastic large cell lymphoma, ALK-negative
* Breast-implant associated anaplastic large cell lymphoma.
* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
Exclusion Criteria
* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Horwitz, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Cancer Center (Data collection only)
Duarte, California, United States
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)
San Diego, California, United States
University of California San Francisco (Data collection only)
San Francisco, California, United States
Stanford University Medical Center (Data collection only)
Stanford, California, United States
University of Colorado (Data Collection Only)
Aurora, Colorado, United States
Yale University (Data Collection Only)
New Haven, Connecticut, United States
University of Miami (Data Collection Only)
Miami, Florida, United States
Moffitt Cancer Center (Data Collection Only)
Tampa, Florida, United States
Emory University (Data Collection Only)
Atlanta, Georgia, United States
Northwestern Medicine (Data Collection)
Chicago, Illinois, United States
Massachusetts General Hospital (Data Collection Only)
Boston, Massachusetts, United States
Dana Farber Cancer Institute (Data Collection Only)
Boston, Massachusetts, United States
Mayo Clinic (Data Collection Only)
Rochester, Minnesota, United States
Washington University (Data Collection Only)
St Louis, Missouri, United States
University of Nebraska (Data collection only)
Omaha, Nebraska, United States
Memorial Sloan Kettering at Basking Ridge (All protocol activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York, United States
Weill Cornell Medical Center (Data Collection Only)
New York, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (All protocol activities)
Uniondale, New York, United States
Ohio State University (Data Collection Only)
Columbus, Ohio, United States
University of Pennsylvania (Data Collection Only)
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital (Data collection only)
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center (Data Collection Only)
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jasmine Zain, MD
Role: primary
Aaron Goodman, MD
Role: primary
Weiyun Ai, MD
Role: primary
Michael Khodadoust, MD
Role: primary
Bradley Haverkos, MD
Role: primary
Francine Foss, MD
Role: primary
Jonathan Schatz, MD
Role: primary
Lubomir Sokol, MD, PhD
Role: primary
Pamela Allen, MD, MSc
Role: primary
Jaehyuk Choi, MD, PhD
Role: primary
Salvia Jain, MD
Role: primary
Eric D Jacobsen, MD
Role: primary
Nora Bennani, MD
Role: primary
Neha Mehta-Shah, MD, MSCI
Role: primary
Matthew Lunning, DO, FACP
Role: primary
Steven Horwitz, MD
Role: primary
Steven Horwitz, MD
Role: primary
Steven Horwitz, MD
Role: primary
Steven Horwitz, MD
Role: primary
Jia Ruan, MD, PhD
Role: primary
Steven Horwitz, MD
Role: primary
Steven Horwitz, MD
Role: primary
John Reneau, MD, PhD
Role: primary
Stefan Barta, MD, MS, MRCPCUK
Role: primary
Pierluigi Porcu, MD
Role: primary
Swami Iyer, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-190
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.